Genentech Rejects Roche Proposal
The American biotech giant Genentech, Inc. has rejected an offer by the Swiss drug-maker Roche to acquire the 44% of Genentech it does not already own, but said it would be willing to consider a higher bid.
The American biotech giant Genentech, Inc. (South San Francisco, CA) has rejected an offer by the Swiss drug-maker Roche (Basel, Switzerland) to acquire the 44% of Genentech it does not already own, but said it would be willing to consider a higher bid.
Genentech said Roche’s offer of $89 a share “substantially undervalues the company” and that it would consider an offer that “reflects the significant benefits that would accrue to Roche as a result of full ownership.”
Last month, Roche had made an offer to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $89 in cash per share. Genentech had formed a special committee to review the proposal.
For more information on the Roche offer, see BioPharm’s previous news coverage.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
